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Discovery of neuroprotective pathways is one of the major priorities for neuroscience. Astrocytes
are natural neuroprotectors and it is likely that brain resilience can be enhanced by mobilizing their
protective potential. Among G-protein coupled receptors expressed by astrocytes, two highly related
receptors, GPR37L1 and GPR37, are of particular interest. Previous studies suggested that these
receptors are activated by a peptide Saposin C and its neuroactive fragments (prosaptide TX14(A)),
which were demonstrated to be neuroprotective in various animal models by several groups. How-
ever, pairing of Saposin C or prosaptides with GPR37L1/GPR37 has been challenged and presently
GPR37L1/GPR37 have regained their orphan status. Here, we demonstrate that in their natural habi-
tat, astrocytes, these receptors mediate a range of effects of TX14(A), including protection from
oxidative stress. The Saposin C/GPR37L1/GPR37 pathway is also involved in the neuroprotective
effect of astrocytes on neurons subjected to oxidative stress. The action of TX14(A) is at least par-
tially mediated by Gi-proteins and the cAMP-PKA axis. On the other hand, when recombinant
GPR37L1 or GPR37 are expressed in HEK293 cells, they are not functional and do not respond to
TX14(A), which explains unsuccessful attempts to confirm the ligand-receptor pairing. Therefore, this
study identifies GPR37L1/GPR37 as the receptors for TX14(A), and, by extension of Saposin C, and
paves the way for the development of neuroprotective therapeutics acting via these receptors.
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MAIN POINTS
1. Prosaptide TX14(A), a fragment of Saposin C, acts via GPR37L1/
GPR37 on astrocytes and protects them from oxidative stress.
2. In HEK293 cells, GPR37L1 and GPR37 are dysfunctional.
3. GPR37L1/GPR37 signaling in astrocytes enables neuroprotection.
1 | INTRODUCTION
Any new target for effective neuroprotective therapy must be actively
explored as it may have major medical and societal impacts. Orphan
G-protein-coupled receptors (GPCRs) are particularly attractive
because they are the most plausible targets for modern small molecule
drugs, but this approach critically depends on identification of their
endogenous agonists. The search for druggable targets in the brain
conventionally focused on neurons, but astrocytes as natural neuro-
protectors represent particularly attractive drug targets. Their neuro-
protective mechanisms are numerous and include uptake of glutamate
to prevent neurotoxicity, regulation of extracellular ions and pH, pro-
vision of antioxidative molecules (e.g., glutathione) and trophic factors,
control of micro-circulation, etc. (Liu, Teschemacher, & Kasparov, 2017).
In 1994, the peptide prosaposin (PSAP) and its fragment Saposin
C (Sap C) were identified as neurotrophic factors using the neuroblas-
toma NS20 line and specific binding of radio-labeled Sap C with a KdSergey Kasparov and Anja G. Teschemacher contributed equally to this study.
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of 19 pM was demonstrated (O'Brien, Carson, Seo, Hiraiwa, & Kishi-
moto, 1994). Soon after it was shown that chronic icv infusion of
recombinant PSAP almost completely prevented ischemia-induced
learning deficits and neuronal loss in gerbils (Sano et al., 1994) and the
existence of a GPCR for the neuroprotective part of Sap C was thus
postulated (Hiraiwa, Campana, Martin, & O'Brien, 1997). The experi-
mental usefulness of PSAP and Sap C is limited by their length but,
luckily, the neuroactive part is rather short and can be mimicked by
peptides known as prosaptides, of which the most studied is prosap-
tide TX14(A). The sequence of TX14(A) is highly evolutionarily con-
served (Supporting Information Figure S1). Although neuroprotective
effects of PSAP fragments were demonstrated in several models
in vitro and in vivo (Campana et al., 1998; Gao et al., 2016; Hozumi
et al., 1999; Otero, Conrad, & O'Brien, 1999), the underlying mecha-
nism remained unclear until 2013, when the two closely related
orphan receptors GPR37L1 and GPR37 (Leng, Gu, Simerly, & Spindel,
1999) were proposed to mediate the actions of PSAP and its mimetics
(Meyer, Giddens, Schaefer, & Hall, 2013).
GPR37L1 is highly expressed by astrocytes, which also express
low levels of GPR37 (Supporting Information Figures S2 and S3; Jolly
et al., 2017; Marazziti et al., 2007; Smith, 2015; Zhang et al., 2014).
GPR37 is highly expressed in dopaminergic neurons and early work
focused on the idea of GPR37 being involved in Parkinson's disease
(Cantuti-Castelvetri et al., 2007; Imai et al., 2001; Marazziti et al.,
2007). The importance of GPR37L1 for brain function has been
recently demonstrated in humans. A point mutation in GPR37L1 leads
to a severe neurological phenotype which includes intractable epi-
lepsy, lethal in some of the affected individuals (Giddens et al., 2017).
GPR37L1- and especially double GPR37L1/GPR37-knockout mice
were highly susceptible to seizures (Giddens et al., 2017). Moreover,
the deletion of GPR37L1 drastically increased the neuronal loss after
an ischemic stroke (Jolly et al., 2017). These and other findings under-
score the importance of GPR37L1 for brain health.
However, the pairing of GPR37L1/GPR37 with PSAP and TX14(A)
(Meyer et al., 2013) was later challenged. It was reported that these
receptors are highly constitutively active and couple via Gs proteins,
rather than the Gi pathway as originally reported (Meyer et al., 2013).
Moreover, on the background of their high constitutive activity,
TX14(A) was ineffective (Coleman et al., 2016; Giddens et al., 2017;
Ngo et al., 2017). Regulation of this constitutive activity was sug-
gested to occur via cleavage of the extracellular part of GPR37L1
(Coleman et al., 2016; Mattila, Tuusa, & Petaja-Repo, 2016). These
reports reinforced the skepticism based on the failure of TX14(A) to
activate GPR37L1/GPR37 using the DiscoverX orphan receptor-
screening panel (Smith, 2015; Southern et al., 2013). Importantly, all
studies reporting high constitutive activity of GPR37L1 and GPR37
and lack of TX14(A) agonism relied on expression of recombinant
GPR37L1 in either HEK293 or CHO cells (Giddens et al., 2017; Ngo
et al., 2017; Southern et al., 2013) or yeast (Coleman et al., 2016).
Thus, the nature of the endogenous agonist of GPR37L1 and
GPR37 is currently elusive.
High constitutive activity of GPR37L1/GPR37 should lead to per-
sistent production of copious amounts of cAMP. However, this has
never been noticed in astrocytes where GPR37L1 is particularly abun-
dant (Supporting Information Figures S2 and S3). To the contrary,
astrocytes vigorously respond to stimuli which increase cAMP produc-
tion (such as agonists of Gs-coupled receptors or low concentrations
of forskolin), indicating that their resting levels of cAMP are not any-
where near saturation (see, for example, Clark and Perkins, 1971;
Goldman and Chiu, 1984; Tardy et al., 1981).
We hypothesized that coupling of GPR37L1/GPR37 in transiently
transfected cell lines does not reveal their true physiological signaling
and reevaluated them in their natural habitat, the astrocytes. Our find-
ings demonstrate that PSAP is, indeed, the natural ligand of
GPR37L1/GPR37 and pave the way for development of neuroprotec-
tive drugs based on this signaling system.
2 | MATERIALS AND METHODS
2.1 | Primary cultures of astrocytes and cortical
neurons
Experiments were performed in accordance with the UK Animals
(Scientific Procedures) Act, 1986, and were approved by the Univer-
sity of Bristol ethics committee.
2.1.1 | Astrocytes
Primary cultures of astrocytes were prepared from the cerebral corti-
ces, cerebellum, and brainstem from Wistar rat pups (P2) following
protocols described previously (1–3). Briefly, the brains of Wistar P2
pups were dissected out, crudely cross-chopped and bathed in a solu-
tion containing HBSS, DNase I (0.04 mg/mL), trypsin from bovine
pancreas (0.25 mg/mL) and BSA (3 mg/mL). The preparation was agi-
tated at 37 C for 15 min. Trypsinization of the brain tissue was termi-
nated by the addition of equal volumes of culture media comprised of
DMEM, 10% heat-inactivated FBS, 100 U/mL penicillin, and
0.1 mg/mL streptomycin and then centrifuged at 2000 rpm, at room
temperature (RT) for 10 min. The supernatant was aspirated, and the
remaining pellet was resuspended in 15 mL HBSS containing BSA
(3 mg/mL) and DNase I (0.04 mg/mL) and triturated gently. After the
cell debris had settled, the cell suspension was filtered through a
40-μm cell strainer (BD Falcon, BD Biosciences, Franklin Lakes, NJ)
and cells were collected after centrifugation. Cells were seeded in a
T75 flask containing culture media (see above) and maintained at
37 C with 5% CO2. Once the cultures reached confluence and
1 week later, the flasks were mildly shaken overnight to remove
microglia and oligodendrocytes. When astrocytes were seeded for
experiments, media was changed to DMEM supplemented with 5%
FBS instead of 10% FBS. This is to reduce the content of PSAP in the
culture media hence make PSAP depletion easier to achieve. Note
that there was no difference in cell growth in the media containing
either 5% or 10% FBS.
2.1.2 | Neurons
Cerebral cortices were dissected out from a litter (8–12) of Wistar rat
embryos on gestation day 18 (E18) and collected in dissection saline
(HBSS, 25.6 mM glucose, 10 mM MgCl2, 1 mM Hepes, 1 mM kynure-
nic acid, 0.005% phenol red, 100 U/mL penicillin, and 0.1 mg/mL
streptomycin). Meninges were removed, and tissues were chopped
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into pieces <1 mm3 and dissociated in 0.25% Trypsin in dis-
section saline in the presence of 3 mg/mL BSA at 37 C for 15 min.
An equal volume of plating media (Neurobasal A with 5% horse serum,
2% B27, 400 nM L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL
streptomycin) was added to terminate the dissociation. Cells were pel-
leted at 2000 rpm for 5 min at room temperature, resuspended in
plating media, and triturated gently. The cell suspension was diluted
appropriately and passed through a 40-μM cell strainer. Approxi-
mately 1 × 105 cells per well were plated on poly-D-lysine-coated
glass cover slips in 24-well plates. Two hours later, the plating media
was replaced with feeding media (Neurobasal A with 2% B27,
800 nM L-glutamine, 20 U/mL penicillin, and 20 μg/mL streptomycin).
On day 5, half of the media was replaced with feeding media in which
glutamine was replaced with 4 μM Glutamax. The antimitotic cytosine
β-D-arabinofuranoside (10 μM) was added to control glial contamina-
tion. Neurons were used for experiments 10 days later.
Neuron/astrocyte co-cultures
Neurons were prepared (see above) and plated at 1 × 105 cells per
well on poly-D-lysine-coated glass coverslips in 24-well plates. Astro-
cyte inserts were prepared by plating astrocytes on poly-D-lysine-
coated cell culture inserts with 1 μm diameter pores (Greiner Bio-One,
Monroe, NC) in the same serum-free media as used for neurons.
Astrocyte inserts were introduced into neuronal cultures as required.
The separation between both cell types allowed secreted molecules
to freely diffuse while preventing direct astrocyte-to-neuron contact.
2.2 | Real-time PCR on primary cultured and acutely
isolated astrocytes
To verify that the expression of GPR37L1 and GPR37 in our cultured
astrocytes is not a result of in vitro conditions, we performed acute
vibro-isolation of cortical astrocytes from P12 rats using a method
recently described by Lalo and Pankratov (2017). Approximately
50 single astrocytes were manually collected from the bottom of a
small Petri dish into a sterile test tube. Power SYBR Green Cells-to-Ct
Kit (Ambion Inc., Austin, TX) was used to reverse transcribe directly
from cultured cell lysates, without isolating RNA. The resulting cDNA
samples were then analyzed using QuantiTect SYBR green PCR kit
(Qiagen, Hilden, Germany) on DNA Engine OPTICON 2 continuous
fluorescence detector, following the manufacturer's protocol. β-Actin
was used as a reference house-keeping gene. All primers were
designed to span at least one intron and to produce products of
~100 bp and prevalidated for their efficiency. Products of PCR reac-
tion were resolved on agarose gel to confirm their sizes (Supporting
Information Figure S3). Sequences of the primers are: β-Actin forward:
CTAAGGCCAACCGTGAAAAG; reverse: GGCATACAGGGACAACA-
CAG; GPR37L1 forward: ATGTTTCTTGCCGAGCAGTG; GPRF37L1
reverse: CCACATGGAATCGGTCTATG; GPR37 forward: TCCAT-
GAGTTGACCAAGAAG; GPR37 reverse: CTATGCACAGTGCACA-
TAAG; GFAP forward: GAGAGGAAGGTTGAGTCGCT; GFAP reverse:
CACGTGGACCTGCTGCTG.
2.3 | Western blotting
For verification of GPR37L1/37 knock-down with adenoviral vectors
(AVV), transduced astrocytes were harvested and placed on ice and
washed with ice-cold phosphate-buffered saline (PBS). The membrane
proteins were then extracted using the Mem-PER eukaryotic mem-
brane protein extraction reagent kit (PIERCE) and purified with SDS-
PAGE sample preparation kit (PIERCE, Appleton, WI). After quantifica-
tion with BCA protein assay kit (PIERCE), 20 μg of membrane protein
per lane were fractionated on a 4–12% Bis–Tris gel (NuPage 4–12%
Bis–Tris Gel, Life Technologies, Carlsbad, CA), and transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore, Burlington,
MA). After blocking with 5% nonfat dry milk (NFDM) in Tris-buffered
saline with 0.1% Tween-20 (TBST) buffer for 45 min at RT, the PVDF
membrane was cut into two parts at 100 kDa size level. The part of
the membrane containing small sized proteins was incubated with pri-
mary antibody to GPR37L1 (1:1000 dilution) or GPR37 (1:1000 dilu-
tion) in 3% NFDM-TBST at 4 C overnight, and the other part of
membrane was incubated with primary antibody to pan-cadherin
(120 kDa) (1:2000 dilution) as a membrane protein loading control, in
3% NFDM-TBST at 4 C overnight. Following incubation with horse-
radish peroxidase conjugated secondary antibody (DAKO, 1:2000
dilution) for 90 min at RT, the immunoreactivities were detected with
Immun-Star Western C chemiluminescent kit (Bio-Rad Laboratories,
Hercules, CA). For the PSAP depletion assay and the proof of the exis-
tence of PSAP in serum-supplemented culture media, we used the
same protocol as described above except that 5 μL of media or elution
from protein A magnetic beads was applied as the sample volume. A
polyclonal rabbit anti-PSAP antibody was employed. For Western
blotting of PSAP in neuron–astrocyte co-culture media, we changed
to the Amersham ECL Plex western blotting system using a low-
fluorescent PVDF membrane (GE Healthcare, Chicago, IL) and Alexa
Fluor 488 secondary antibody-conjugated goat anti-rabbit. Protein
transfer and membrane blocking was the same as in the above proto-
col. Membranes were incubated with anti-PSAP (1:500 dilution) over-
night at 4 C. Secondary antibody Alexa Fluor 488 was incubated for
1 hr in the dark at room temperature. Before imaging, the membrane
was thoroughly washed. Signal was detected by scanning the mem-
brane on a fluorescent laser scanner (Typhoon, GE Healthcare).
2.4 | Generation of knock-down AVV
AVV for the knock-down experiments were based on a modified Pol II
miR RNAi Expression Vector system (Invitrogen) and our previous
work (Liu, Xu, Paton, & Kasparov, 2010). Three AVV were con-
structed, namely, AVV–CMV–EmGFP–miR155/GPR37L1, AVV–
CMV–EmGFP–miR155/GPR37, and AVV–CMV–EmGFP–miR155/
negative. The first two were used for knocking down GPR37L1 and
GPR37 in astrocytes, respectively. The third one is a negative control,
harboring a miRNA sequence that can form a hairpin structure that is
processed into mature miRNA but is predicted not to target any
known vertebrate gene. All three vectors were made based on
BLOCK-iT Pol II miR RNAi Expression Vector Kit with EmGFP
(Invitrogen, Carlsbad, CA). This system supports chaining of miRNAs,
thus ensuring co-cistronic expression of multiple miRNAs for knock
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down of a single target. Three sets of two complementary single-
stranded DNA micro-RNA sequences (targeting different regions of
the same gene) for GPR37L1 and GPR37 were designed by the
BLOCK-iT RNAi Designer (Invitrogen). The complementary single-
stranded oligos were then annealed and cloned into the linearized
pcDNA 6.2-GW/EmGFP–miR vector. The pre-miRNA expression cas-
settes were transferred into an adeno shuttle plasmid pXcX–Sw-linker
(Duale, Kasparov, Paton, & Teschemacher, 2005), resulting in con-
struction of pXcX–CMV–EmGFP–miR155/GPR37L1, pXcX–CMV–
EmGFP–miR155/GPR37 and pXcX–CMV–EmGFP–miR155/negative.
AVV were then produced by homologous recombination of shuttle
and the helper plasmid pBHG10 in HEK293 cells. The media was col-
lected for subsequent rounds of AVV proliferation in HEK293 cells
until cytopathic effects were achieved. AVV were purified using CsCl
gradient protocols. Titers were established using an immunoreactivity
spot assay as described previously (Duale et al., 2005).
2.5 | PSAP depletion
To deplete PSAP from culture media (DMEM supplemented with 5%
FBS), initially, 25 μL of Protein A Magnetic Beads (NEB) per 200 μL
media were added and incubated for 1 hr at 4 C. Magnetic field was
applied for 30 s to pull beads to the side of the tube and the superna-
tant was transferred to a new tube. This step is required to remove
non-specific binding proteins. Then, 5 μL of anti-PSAP antibody
(500 μg/mL) were added to the supernatant and incubated for 1 hr at
4 C. Protein A magnetic beads were used again to pull down the
antibody-bound PSAP. Western blot was used to verify the efficient
removal of PSAP which could then be recovered from the beads
(Supporting Information Figure S4).
2.6 | cAMP assays
Two types of detection were used.
2.6.1 | Luminescence activity-based GloSensor assay
(Promega)
The GloSensor assay uses genetically encoded biosensor variants with
cAMP binding domains fused to mutant forms of Photinus pyralis lucif-
erase. The luminescence of the reporter increases directly proportion-
ally to the amount of cAMP present. Astrocytes were seeded in
96-well plates and transduced with an AVV bearing the CMV-driven
GLO22F at multiplicity of infection (MOI) 10. After 24 hr transduc-
tion, media was exchanged for 100 μL HEPES-buffered HBSS
(pH 7.6). Cells were then incubated with 0.731 mM beetle luciferin
for 2 hr in the dark. After baseline reading, NKH477 and/or TX14
(A) were added to the wells and incubated for 20 min. Luminescence
measurements were obtained using a Tecan microplate reader
(Infinite M200 PRO).
2.6.2 | FRET-based cAMP assay
Two to three days before recordings, astrocytes were plated onto
coverslips in prosaposin-depleted media (PDM) and transduced with
an AVV to express an Epac [Exchange protein directly activated by
cAMP)-based FRET sensor (kindly provided by K. Jalink, Amsterdam;
Klarenbeek, Goedhart, van Batenburg, Groenewald, & Jalink, 2015;
Klarenbeek & Jalink, 2014) specifically in astrocytes. PDM was
exchanged daily. For recording, coverslips were placed into a cham-
ber on a confocal microscope and continuously superfused with
HEPES-buffered solution (HBS; in mM: NaCl 137, KCl 5.4, Na2HPO4
0.34, KH2PO4 0.44, CaCl2 1.67, MgSO4 0.8, NaHCO3 4.2, HEPES
10, Glucose 5.5; pH 7.4, 31.4 C). After taking baseline readings of
astrocytes in the field of view, cells were exposed to 5 min of
NKH477 (0.5 μM), alone or in combination with TX14(A) (100 nM).
Fluctuations in cAMP were monitored through CFP/YFP (465–-
500 nm/515–595 nm bands) emission ratios upon 458 nm light
excitation. Images were acquired every 4 s. All FRET ratios were nor-
malized to baseline.
2.7 | PRESTO-Tango β-arrestin-recruitment assay
To measure receptor activation, the PRESTO-Tango β-arrestin-
recruitment assay was performed as previously described, with modi-
fications (Kroeze et al., 2015). HTLA cells, a HEK293 cell line stably
expressing a tTA-dependent luciferase reporter and a β-arrestin2-TEV
fusion gene, were used. The cells were maintained in DMEM media
supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL
streptomycin, 2 μg/mL puromycin, and 100 μg/mL hygromycin B. For
transfection, HTLA cells were plated in 96-well white polystyrene
plates (Greiner Bio-One, Monroe, NC) in DMEM media supplemented
with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at a
density of 4 × 105 cells/mL. For measuring activation of GPR37 and
GPR37L1 by TX14(A) stimulation, PDM was used instead. After 16 hr,
cells were transfected with the plasmid containing the GPR37 or
GPR37L1 ORF (Addgene, Cambridge, MA) using Trans-IT 293 (Mirus
Bio, Madison, WI) according to manufacturer's protocol. On the next
day, drugs were added in assay buffer (20 mM HEPES in HBSS,
pH 7.4) and left to incubate for 24 hr. Solutions were aspirated, and
80 μL per well of Bright-Glo solution (Promega, Madison, WI) diluted
20-fold in assay buffer was added to each well in the dark. Following
20 min of incubation, luminescence measurements were obtained
using a Tecan microplate reader (Infinite M200 PRO, Tecan Trading
AG, Männedorf, Switzerland).
2.8 | Scratch wound assay
A wound recovery assay was carried out to analyze the migration of
astrocytes using the IncuCyte system (Essen BioScience Inc., Ann
Arbor, MI). Primary astrocytes were seeded in ImageLock 96-well
plates (4,379, Essen BioScience) at a density of 4 × 104 per well.
After 24 hr, standardized and reproducible (700–800 μm wide)
scratch “wounds” were created in all wells using a dedicated device.
Cultures were exposed to different testing conditions, for example,
stressors, and were maintained and imaged at hourly intervals up
to 72 hr.
Cell density was measured in the scratch area and compared to
undisrupted adjacent monolayer. Relative wound density (%), a mea-
sure of wound recovery, was calculated using the formula: Relative
wound density (%) = (Density of wound region at certain time
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point – Initial density of wound region)/(Density of intact cell region
at certain time point − Initial density of wound) × 100%.
2.9 | DAPI staining
Astrocytes were seeded in 96-well plate (1 × 104 per well) and fixed
in 4% paraformaldehyde for 5 min, washed in PBS three times for
5 min each time before and after incubating with 1 μg/mL DAPI for
10 min. Round and whole nuclei in nine fields of view per well were
counted using ImageJ (NIH, Bethesda, MD).
2.10 | BrdU incorporation assay
To detect cell division, astrocytes were seeded in a 96-well plate
(4 × 103 per well) in media supplemented with 5% FBS or PDM and
cultured for 1 day. BrdU was added to the wells at a final concentra-
tion of 10 μM. After 24 hr, cells were fixed with 4% paraformaldehyde
in PBS (pH 7.4) for 10 min at room temperature and permeabilized
with 0.1–0.25% Triton X-100 in PBS. Cells were then incubated with
1 M HCl for 30 min, followed by primary antibody incubation with
mouse monoclonal anti-BrdU antibody (1:100) containing 2.5% goat
serum at 4 C overnight. Before imaging, cells were incubated with
Alexa Fluor 488-conjugated goat anti-mouse secondary antibody for
30 min at room temperature.
2.11 | Lactate dehydrogenase release assay
Lactate dehydrogenase (LDH) release from damaged cells was
assessed colorimetrically with LDH Cytotoxicity Assay Kit (Pierce)
according to the manufacturer's instructions. Activity is proportional
to colorimetric reduction of tetrazolium salt measured at 490 nm.
Cytotoxicity was normalized to maximal LDH activity as released from
cells acutely exposed to Triton X-100, and calculated using the for-
mula: % Cytotoxicity = (Compound-treated LDH activity – Spontane-
ous LDH activity)/(Maximum LDH activity – Spontaneous LDH
activity) × 100%.
To determine the protective effect of prosaptide TX14
(A) against oxidative stress on primary astrocytes, cells were seeded
in triplicates in 96-well plates (4 × 104 per well) in PDM and trans-
duced with AVV–CMV–EmGFP–miR155/negative (labeled as
miRNA-negative in the figures), or a mixture of AVV–CMV–EmGFP–
miR155/GPR37L1 and AVV–CMV–EmGFP–miR155/GPR37 (molar
ratio 3:1, labeled as miRNA-GPR37L1/GPR37 in figures). 24 hr later,
the media was replaced by fresh PDM and cells were treated with
H2O2 (250 μM), staurosporine (200 nM), or rotenone (100 μM) for
5 hr in the presence or absence of TX14(A). The media was then
replaced by fresh PDM with or without TX14(A). Cells were incu-
bated for a further 24 hr before carrying out the LDH reaction on
50 μL of media.
For the protective effect of astrocytes on stressed neurons in
the co-culture system, astrocytes or neurons were transduced with
AVV at MOI 10. For astrocytes, cells were transduced at the time of
plating on cell culture inserts. For neurons, cells were transduced on
day 3 after preparation and then plated. After 24 hr, media were
replaced. Cells were cultured for 7 more days before they were
treated with H2O2 (250 μM, 1 hr), rotenone (50 μM, 2 hr), or staur-
osporine (100 nM, 2 hr). Stressors were then removed and neurons
were incubated with or without astrocytes inserts. After 24 hr, the
LDH reaction was carried out using 50 μL of media. Cytoprotection
was calculated using the formula: % Cytoprotection = % cytotoxic-
ity in the control condition − % cytotoxicity in the experimental
condition.
2.12 | Reagents
Cell culture and cell-based assays related: Beetle luciferin potassium
salt (E1602, Promega); B27 (17,504,044, Life Technologies, Carlsbad,
CA); Bovine serum albumin (BSA) fraction V (A3294, Sigma, Kawasaki,
Kanagawa Prefecture, Japan); BrdU (AB142567, Abcam); Bright-Glo
reagent (E2610, Promega); cytosine β-D-arabinofuranoside (C1768,
Sigma); DNase I (D5025, Sigma); DAPI (D9542, Sigma); Dulbecco's
modified eagle medium (DMEM; 61,965, Life Technologies); fetal
bovine serum (FBS, 10082147, Life Technologies); GlutaMax
(35,050,038, Life Technologies); L-Glutamine (2,503,008, Life Technol-
ogies); Hank's balanced salt solution (HBSS; 14175-129, Invitrogen);
HEPES (H3375, Sigma); horse serum (H1138, Sigma); hygromycin B
(H3274, Sigma); kynurenic acid (K3375, Sigma); neurobasal-A media
(10,888,022, Life Technologies); penicillin/streptomycin (15140-122,
Life Technologies); poly-D-lysine (A-003-E, Millipore); protein A mag-
netic beads (NEB, S1425S); puromycin (P8833, Sigma); Triton X-100
(T8787, Sigma); Trypsin (type III, bovine fraction; T9935, Sigma).
Ambion Power SYBR Green Cells to Ct kit (4402953) was used to ver-
ify GPR37L1 and GPR37 expression in cultured and acutely isolated
astrocytes.
Antibodies: Alexa Fluor 488-conjugated goat anti-rabbit second-
ary antibody (R37116, Life Technologies); Alexa Fluor 488-conjugated
goat anti-mouse secondary antibody (R37120, Life technologies);
GPR37 L1 antibody (AB151518, Abcam, Cambridge, UK); GPR37 anti-
body (14820–1-AP, Proteintech, Chicago, IL); mouse monoclonal anti-
BrdU antibody (GTX27781, GeneTex, Irvine, CA); pan-cadherin anti-
body (AB6529, Abcam); rabbit anti-PSAP antibody (AB68466,
Abcam).
Drugs: 6-BenZ-cAMP (B009-10, BIOLOG Life Science Institute,
Bremen, Germany); 8-pCPT-20-O-Me-cAMP (C041-05, BIOLOG Life
Science Institute); H2O2 (H1009, Sigma); Pertussis toxin (3,097, Tocris
Bioscience, Bristol, UK); NKH 477 (SC-204130, Santa Cruz Biotech-
nology, Dallas, TX); Prosaptide TX14(A) (5,151, Tocris); rotenone
(R8875, Sigma); Staurosporine (10,042,804, Fisher Scientific, Hamp-
ton, NH).
All other chemicals were from Sigma.
2.13 | Statistical analysis
All data analysis was performed with GraphPad Prism 7 (GraphPad
Software Inc., La Jolla, CA). One-way ANOVA with post hoc analysis
was used, unless otherwise stated. *p < .05, **p < .01, ***p < .001,
****p < .0001. Grouped data are presented as mean  SD, unless oth-
erwise stated.
Further details of statistical procedures can be found in the Sup-
porting Information as “Supplemental Statistics.”
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3 | RESULTS
3.1 | GPR37L1/GPR37 activation by prosaptide
inhibits cAMP production in astrocytes but not in
HEK293 cells
Consistent with published information, GPR37L1 is strongly
expressed by cultured rat astrocytes which also express GPR37 at a
lower level. We have also confirmed that both receptors are present
in acutely isolated cortical astrocytes from P12 rats, consistent with
various published transcriptomes (Supporting Information Figures S2
and S3). Therefore, we always targeted both receptors simultaneously.
A powerful double knock-down of GPR37L1 and GPR37 was
achieved by modifying conventional micro-RNA based cassettes to
incorporate three anti-target hairpins fused to the 30-end of the Emer-
ald green protein (Figure 1a; Liu et al., 2010). These “triple-hit” cas-
settes suppressed GPR37L1 and GPR37 protein expression below our
detection limits whereas a negative control sequence had no impact
(Figure 1b). The efficacy of the knock-down was additionally con-
firmed using real-time PCR (Supporting Information Figure S5). To
ensure maximal transduction of astrocytes we used AVV which are
exceptionally effective tools for these cells (Supporting Information
Figure S6).
To assess intracellular cAMP changes, AVV were also used to
express the Glosensor biosensor (Promega). Baseline levels of cAMP
were raised ~20-fold using a water soluble forskolin analogue,
NKH477. On that background, TX14(A) concentration dependently
decreased cAMP with an IC50 of 17.8 nM (Figure 1c). The maximal
concentration of TX14(A) used (200 nM) inhibited NKH477-mediated
cAMP production by ~40% (Figure 1c). The decrease of cAMP
induced by TX14(A) was pertussis toxin (PTX) sensitive (Figure 1d).
Expression of the negative control miRNA vector had no effect while
combined knock-down of the GPR37L1 and GPR37 receptors
completely obliterated the TX14(A)-mediated decrease in cAMP levels
(Figure 1c). In addition, we employed an EPAC-based high affinity
FRET sensor for cAMP (Klarenbeek et al., 2015) to visualize cAMP
dynamics following TX14(A) application and found that TX14
(A) (100 nM) significantly reduced the NKH477-evoked rise in FRET
ratio (Figure 1e,f ).
Several previous reports which failed to confirm the TX14
(A) effect on GPR37L1 and GPR37 used transiently transfected
HEK293 cells. To verify that in HEK293 cells GPR37L1 and GPR37
signaling is different to that in astrocytes (Figure 1c–f ), we used the
PRESTO-Tango system (Kroeze et al., 2015). It provides GPCRs
adapted for transient expression in a HEK293 line, modified to detect
agonist-induced GPCR internalization. In that assay, GPR37 was con-
stitutively active (compared to the baseline with ADRA1; Supporting
Information Figure S7) and both receptors were insensitive to prosap-
tide TX14(A) (Figure 2), while the α-adrenoceptor 1a (ADRA1a) dem-
onstrated an appropriate response (Supporting Information Figure S7).
The most likely explanation for this difference is that GPR37L1 and
GPR37 require some additional proteins for their correct function
which are lacking in HEK293 cells. Further analysis of this issue is out-
side of the scope of the current study.
3.2 | PSAP and TX14(A) acting via GPR37L1/GPR37
are essential for the motility of astrocytes
Body fluids, such as milk, blood, and cerebrospinal fluid, contain
PSAP (Kishimoto, Hiraiwa, & O'Brien, 1992). Most media used for
culturing are supplemented with FBS. Unsurprisingly, PSAP was pre-
sent in FBS-supplemented media (Supporting Information
Figure S4). We studied the effect of PSAP depletion, using immu-
noadsorption (Supporting Information Figure S4), on the motility of
astrocytes in a wound scratch assay. Reproducible (700–800 μM
wide) scratch wounds were created in astrocyte monolayers. In
FBS-containing media, the wound essentially closed within 48 hr
(Figure 3a; Supporting Information Movie S1). This process was
drastically slowed down by PSAP depletion. About 100 nM TX14
(A) almost completely compensated for the loss of PSAP (Figure 3a,
c; Supporting Information Movies S2 and S3). Importantly, knock-
down of GPR37L1/GPR37 in astrocytes blocked the ability of TX14
(A) to facilitate wound closure while the control vector was ineffec-
tive (Figure 3c, Supporting Information Movies S4 and S5). Astro-
cytes divide in culture, albeit very slowly, but neither depletion of
PSAP nor addition of TX14(A) affected the number of cells in cul-
tures (Figure 3d) nor the number of newly divided cells based on
BrdU staining (Figure 3e). Therefore, the effects of PSAP and TX14
(A) in the scratch assay are due to their effect on the motility of
astrocytes.
Stimulation of adenylate cyclase with NKH477 (1–10 μM)
greatly slowed down wound closure, as did the cAMP analogue
6-benz-cAMP (250–1,000 μM), a selective PKA activator, in a
concentration-dependent manner (Figure 4a). The cAMP analogue
8-pCPT-20-O-Me-cAMP (250–1,000 μM) which specifically activates
EPAC (cAMP-GEF) had no effect (Figure 4a). Interestingly, nonse-
lective stimulation of cAMP production by NKH477 as well as
stimulation of PKA by 6-BenZ-cAMP and of EPAC by 8-pCPT-20-
O-Me-cAMP reduced proliferative activity of astrocytes (Figures 3d
and 4b). As all three cAMP raising drugs had a similar effect on
cell numbers but different effects on wound closure dynamics,
there appears to be no direct relationship between these two
effects of cAMP. Taken together, the data indicate that the key
mechanism of wound closure which is regulated via the GPR37L1/
GPR37 axis is the lateral movement of astrocytes, rather than their
division.
3.3 | PSAP and prosaptide protect astrocytes from
oxidative stress damage via GPR37L1/GPR37
Exposure of astrocytes to H2O2, rotenone, or staurosporine drastically
inhibited their ability to close the wound in PSAP-depleted media but
TX14(A) rescued the stressed astrocytes' wound closure capacity
(Figure 5a). This effect of TX14(A) was eliminated by the knock-down
of GPR37L1/GPR37 in astrocytes, while the control knock-down vec-
tor was ineffective (Figure 5a).
It has been previously reported that the death of cortical astro-
cytes triggered by H2O2 can be reduced by TX14(A) (Meyer et al.,
2013). We adjusted concentrations and exposure time of H2O2, rote-
none, and staurosporine to evoke a comparable degree of cytotoxicity
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as assessed by LDH release assay (Figure 5b). In PSAP-depleted
media, neither GPR37L1/GPR37 knock-down, nor the negative con-
trol vector, changed the cytotoxic impact of stressors. TX14
(A) strongly reduced cytotoxicity which was particularly prominent in
the case of staurosporine, and this was prevented by GPR37L1/
GPR37 knock-down (Figure 5b).
3.4 | Astrocytic GPR37L1/GPR37 signaling
contributes to the protection of the cortical neurons
from damage by oxidative stressors
Neuronal cultures were subjected to the same oxidative stressors as
above and conditions were adjusted to trigger a comparable degree of
damage, based on LDH release. After removal of the stressors,
FIGURE 1 TX14(A) acting on GPR37L1/GPR37 reduces cAMP levels in astrocytes. (a) Layout of the adenoviral vectors for knock-down of
GPR37L1 and GPR37. Each vector allows co-cistronic expression of three pre-miRNAs targeting different regions of the target gene.
AVV = human adenoviral vectors serotype 5; CMV = human cytomegalovirus promoter; EmGFP = Emerald green fluorescent protein;
miR155 = flanking pre-miRNA sequence derived from miR-155. (b) Western blot confirms that AVV–CMV–EmGFP–miR155/GPR37L1 and
AVV–CMV–EmGFP–miR155/GPR37 (MOI 10) efficiently knock-down GPR37L1 and GPR37 in astrocytes. AVV–CMV–EmGFP–miR155/
negative is a control vector with hairpin sequence relevant to no known vertebrate gene. (c) Concentration–response curves for inhibition of
cAMP production by TX14(A) in astrocytes pretreated with 1 μM NKH477. Cells were transduced with AVV–CMV–Glosensor and either
AVV–CMV–EmGFP (control), a mixture of AVV–CMV–EmGFP–miR155/GPR37L1 and AVV–CMV–EmGFP–miR155/GPR37 to knock-down
GPR37L1/GPR37, or with AVV–CMV–EmGFP–miR155/negative (n = 4, triplicates). (d) AVV–CMV–Glosensor transduced astrocytes were
pretreated with PTX (20 hr, 100 ng/mL). About 100 nM TX14(A)-induced cAMP reduction in astrocytes was PTX sensitive (n = 12,
***p < .001 vs. indicated group, one-way ANOVA with Turkey's post hoc analysis). (e): Astrocytes expressing an EPAC-based cAMP sensor
were kept in PSAP-depleted media overnight and were stimulated with NKH477 (0.5 μM) in the absence or presence of TX14(A) (100 nM).
TX14(A) decreased the transient cAMP signal; average of 58 astrocytes from four experiments. (f ) Pooled data from (e) shows significantly
decreased FRET ratio peaks with TX14(A) (n = 58 = ****p < .0001, paired t test) [Color figure can be viewed at wileyonlinelibrary.com]
LIU ET AL. 7
astrocytes were introduced into the wells on elevated membranes,
thereby preventing direct cell–cell contact (Figure 6a). Astrocytes
exerted a strong protective effect on the neurons which was directly
proportional to the quantity of astrocytes (Figure 6b; Supporting
Information Figure S8). About 75 k astrocytes per well provided a
near-maximum neuroprotective effect and this astrocyte density was
used for further experiments.
TX14(A) applied directly to damaged cultured neurons at 100 nM,
provided a slight but significant protection against the stressors
(Figure 6c). This indicates that either neuronal GPR37L1/GPR37
receptors, or the few astrocytes remaining in the neuronal cultures,
could be contributing to the neuroprotective actions of PSAP.
Figure 6d demonstrates that, for each of the three stressors, co-
culturing with astrocytes reduced LDH release by ~35–45%. Impor-
tantly, the media used in these experiments was FBS-free and con-
tained no added PSAP. However, when anti-PSAP antibodies were
added, the cytoprotective effect of astrocytes was dramatically
reduced (Figure 6d). This strongly suggests that endogenous PSAP
(or Sap C) in the co-culture system is important for the cytoprotective
effect of astrocytes. We were able to immunodetect directly the
increase in PSAP in co-culture media in response to H2O2 stress
applied to neurons (Supporting Information Figure S9), although
the cellular source of this the stress-induced PSAP surge is cur-
rently unknown. Knock-down of GPR37L1/GPR37 selectively in
astrocytes limited astrocyte-mediated neuroprotection to a degree
comparable to PSAP depletion (Figure 6d). Interestingly, application
of the same knock-down AVV to neurons had no effect. These
results are consistent with the idea that stress-induced PSAP
release and astrocytic GPR37L1/GPR37 signaling are critical for
PSAP action.
4 | DISCUSSION
The key message of this study is that the original coupling of PSAP
and its prosaptide fragments to GPR37L1 and GPR37 suggested by
Meyer et al. (2013) was correct. This implies that we can expect small
molecules based around the structure of TX14(A) be astro- and
neuroprotective.
4.1 | Neuroprotection by PSAP
The first cells used to demonstrate a protective potential of PSAP
were mouse neuroblastoma NS20Y and human neuroblastoma SK-N-
MC cells (O'Brien et al., 1994). Interestingly, the neuroblastoma lines
closely related to SK-N-MC express substantial levels of GPR37
(Harenza et al., 2017). Published transcriptomes of astrocytes
(Anderson et al., 2016; Chai et al., 2017; Zhang et al., 2014; Zhang
et al., 2016) and our own data (Supporting Information Figures S2 and
S3) unequivocally demonstrate that astrocytes of various parts of the
central nervous system express high levels of GPR37L1 while the level
of GPR37 is generally much lower. Cytoprotective and “trophic”
effects of PSAP and its fragments were found in diverse models and
species. Prosaptides improved the outcome of sciatic nerve damage in
guinea pigs (Kotani et al., 1996), alleviated the ischemia-induced mem-
ory deficits in gerbils (Kotani et al., 1996), reduced neuropathy in dia-
betic rats (Calcutt et al., 1999), and the behavioral and anatomical
detriments caused by brain wound insult in rats (Hozumi et al., 1999).
A stabilized TX14(A)-like peptide, retro–inverso prosaptide D5, was
neuroprotective in rats (Lu, Otero, Hiraiwa, & O'Brien, 2000) and ame-
liorated hyperalgesia in a model of neuropathic pain (Yan, Otero, Hir-
aiwa, & O'Brien, 2000). The neuroprotective effects of TX14(A) were
confirmed by another group (Jolivalt, Dacunha, Esch, & Calcutt, 2008;
Jolivalt, Ramos, Herbetsson, Esch, & Calcutt, 2006; Sun et al., 2002).
An 18-amino acid long prosaptide was also protective in a model of
dopaminergic neuron damage (Gao et al., 2013; Sun et al., 2002).
Therefore, there is solid evidence for the neuroprotective potential of
this pathway.
4.2 | PSAP-GPR37L1/GPR37 pairing
All these effects obviously called for the development of a neuropro-
tective therapy, but this opportunity could not be realized in the
absence of cognate receptors. The study by Meyer et al. (2013)
FIGURE 2 GPR37L1 and GPR37 are non-responsive to prosaptide
TX14(A) in PRESTO-Tango assay in HEK293 cells. PRESTO-Tango
uses clones of numerous human GPCR, C-terminally tagged with a
special signaling element. These receptors need to be expressed in a
specially designed clone of HEK293 cells. Agonist binding triggers
receptor internalization and eventually leads to expression of
luciferase and luminescence. Two concentrations of plasmid DNA
were used to express the tagged receptors. GPR37 exhibits strong
constitutive activity, especially when using 0.1 μg/μL. Values obtained
with 0.1 μg of GPR37 DNA could not be fitted with the regression
algorithm of Prism software, hence no line is shown (n = 6) [Color
figure can be viewed at wileyonlinelibrary.com]
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strongly suggested that these are the orphan receptors GPR37L1 and
GPR37. Some of the effects were demonstrated in HEK293 cells, but
the most striking protective effect of TX14(A) was observed in cul-
tured astrocytes. The findings of Meyer et al. (2013) were later criti-
cized, the key concerns being the high concentration of TX14(A) used,
the small magnitude of the Gi-mediated inhibitory effect on cAMP
concentration and the failure to detect TX14(A) agonism in a
β-arrestin-based DiscoverX assay (Smith, 2015; Southern et al., 2013).
Other recent studies reported high constitutive activity of GPR37L1
and GPR37 and lack of a TX14(A) effect in either HEK293 cells or
yeast (Coleman et al., 2016; Giddens et al., 2017; Ngo et al., 2017;
Southern et al., 2013).
Our findings, however, are consistent with the conclusions drawn
by (Meyer et al., 2013). The presence of PSAP in the media or addition
of TX14(A) had a powerful effect on astrocytic motility and protected
them against oxidative stressors. In all cases, this action could be
completely prevented by knocking down GPR37L1/GPR37
(Figures 3a,c and 5). Moreover, when astrocytes were used to rescue
neurons subjected to oxidative stress, removal of GPR37L1/GPR37
only from astrocytes was sufficient to significantly weaken their neu-
roprotective capacity and block the protective action of TX14(A) (Fig-
ure 6d). TX14(A) at a fairly high concentration (100 nM) had a weak
direct protective effect on stressed neurons which is unlikely to make
a major contribution to the neuroprotection seen in the presence of
FIGURE 3 PSAP/GPR37L1/GPR37–mediated signaling is essential for migration of astrocytes in the scratch assay and the effect of PSAP is
mimicked by TX14(A). (a) Astrocytes move into a wound in media containing 5% FBS and in PDM (prosaposin-depleted media) supplemented
with 100 nM TX14(A) but the movement is inhibited in absence of PSAP. Representative images at 0, 24, and 48 hr post scratch. See also
Supporting Information Movies SS1–SS3. (b) Dynamics of the relative wound density under conditions shown in a (n = 3, triplicates). (c) Relative
wound density 48 hr post scratch for astrocytes incubated in FBS-containing media, PDM, PDM + TX14(A), PDM + TX14(A) + both knock-down
vectors and PDM + TX14(A) + knock-down control vector n = 6, triplicates, ***p < .001 vs. indicated group, one-way ANOVA with Turkey's post
hoc analysis). (d): DAPI staining revealed no significant differences in the cell density between astrocytes cultured in media (+FBS), PDM and
PDM supplemented with TX14(A) (100 nM; n = 15). (e): The addition of TX14(A) to PDM does not affect the numbers of new astrocytes based
on BrdU staining (n = 7, triplicates) [Color figure can be viewed at wileyonlinelibrary.com]
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astrocytes (Figure 6c). At least, application of the knock-down strat-
egy to neurons was without an obvious effect (Figure 6d).
Therefore, by several approaches, we demonstrate that the
effects of PSAP and TX14(A) on astrocytes are invariably dependent
on GPR37L1/GPR37. The partial protection provided to injured neu-
rons by co-cultured astrocytes to some extent also depends on this
signaling pathway. Given that only removal of GPR37L1/GPR37 from
astrocytes, but not neurons interfered with neuroprotection in this
paradigm, the likeliest scenario is that PSAP acts as an autocrine signal
on the receptors located on the astrocytes to recruit additional, uni-
dentified, neuroprotective molecules (Figure 7).
Previous studies in mice lacking either of the two receptors dem-
onstrated various, albeit relatively mild, phenotypes but, to the best of
our knowledge, the possibility of compensation by the remaining
receptor in a single knockout scenario has never been explored. This
could be the reason why the pro-seizure phenotype of double
GPR37L1/GPR37 knockout mice is so severe (Giddens et al., 2017).
Recent demonstration of a lethal neurological phenotype in humans
with a point mutation in GPR37L1 (Giddens et al., 2017) suggests that
GPR37L1 is potentially indispensable for the health of the human
brain. A drastic increase in neuronal loss after an ischemic stroke in
GPR37L1 knockout mice (Jolly et al., 2017) further reinforces the
importance of these receptors.
4.3 | Coupling
The first study to indicate that a Gi-coupled receptor may mediate the
action of PSAP found that pretreatment with PTX inhibited agonist-
stimulated binding of [35S]-GTPγS (Hiraiwa et al., 1997). Strikingly, it
also demonstrated that Sap C interacts with a receptor of ~54 kDa,
corresponding almost exactly to the molecular mass of GPR37L1
(Giddens et al., 2017). In our study in astrocytes, TX14(A) inhibited
cAMP production by ~40% from an elevated level set by the forskolin
analogue (Glosensor assay). The effect of TX14(A) was PTX sensitive
and the IC50 compares with that of numerous other GPCR agonists.
Removal of GPR37L1 and GPR37 completely prevented the effect of
TX14(A). These results confirm the original report (Meyer et al., 2013)
FIGURE 4 cAMP in astrocytes affects wound closure in the scratch
assay. (a) A scratch wound was created in astrocyte monolayers
cultured in FBS-containing media or PDM supplemented with
100 nM TX14(A). Drugs were added and dynamics of the wound
closure was monitored for 72 hr (n = 5, triplicates). (b) DAPI staining
of astrocytes shows that NKH477 (10 μM), 6-BenZ-cAMP (500 μM),
and 8-pCPT-20-O-Me-cAMP (1,000 μM) significantly decreased cell
numbers as compared to control (n = 4, triplicates). In both cases, one-
way ANOVA with Dunnett's post hoc analysis. **p < .01, ***p < .001
vs. control [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 5 TX14(A) acts via GPR37L1 and GPR37 to protect primary
astrocytes against toxicity induced by H2O2, staurosporine or
rotenone. (a) Pre-exposure to stressors (5 hr) drastically reduce
relative wound density recorded at 48 hr in PDM. TX14(A) (100 nM)
rescued astrocytes bringing wound density close to normal (compare
to Figure 3). GPR37L1/GPR37 knock-down prevented the protective
effect of TX14(A), while the control vector had no effect (n = 6,
triplicates, ***p < .001 vs. indicated group). (b) LDH release was used
as a measure of cytotoxicity, 24 hr after exposure of astrocytes to
oxidative stress. In PDM, manipulation of GPR37L1/GPR37 had no
effect. TX14(A) (100 nM) protected them from damage but only when
they were expressing GPR37L1/GPR37, (n = 6, triplicates, **p < .01,
***p < .001 vs. control group, for example, PDM groups). One-way
ANOVA with Bonferroni's post hoc analysis [Color figure can be
viewed at wileyonlinelibrary.com]
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that GPR37L1/GPR37 are Gi-coupled receptors. Coupling to other G-
proteins needs to be investigated further.
In the wound scratch assay, PSAP and TX14(A) were permissive to
the spread of astrocytes into the barren area. This was due to an effect
on lateral motility (Figure 3d,e). Again, this effect was completely
prevented by knock-down of the two receptors (Figure 3c). Interestingly,
stimulants of the cAMP pathway, the adenylyl cyclase activator
NKH477, and two pathway-biased agonists, 6-BenZ-cAMP, and
8-pCPT-20-O-Me-cAMP, reduced the speed of division of cultured
astrocytes (Figure 4b) but only 6-BenZ-cAMP which predominantly acti-
vates PKA (Bos, 2003) concentration-dependently suppressed spread of
the astrocytes into the wounded area (Figure 4a). Therefore, the motility
of astrocytes is regulated by PKA, rather than EPAC-regulated proteins.
TX14(A) did not interfere with the reduction in mitotic activity by either
of the cAMP analogs (Figure 4b). The mechanism by which PKA regu-
lates astrocyte motility is currently unknown.
4.4 | Controversy related to PSAP-GPR37L1/GPR37
pairing
Neither HEK293 cells nor yeast used in the recent conflicting studies
(Coleman et al., 2016; Giddens et al., 2017; Ngo et al., 2017) express
GPR37L1 or GPR37 natively, nor were they ever demonstrated to be
responsive to PSAP or prosaptides. These cells might not necessarily
recapitulate the intracellular environment of astrocytes and neurons
which are the natural habitats of GPR37L1 and GPR37. Our experi-
ments using PRESTO-Tango confirmed that neither GPR37L1 nor
GPR37 respond to TX14(A) in HEK293 cells (Figure 2).
Serum-containing media can mask the effects of GPR37L1/
GPR37 ligands because it contains considerable levels of PSAP. Most
likely astrocytes, neurons or both can secrete some PSAP in vivo. This
was visible in the “rescue” experiments where astrocytes reduced the
damage caused to neurons by added stressors. In these experiments,
anti-PSAP antibodies reduced neuroprotection even though the media
was nominally devoid of PSAP. In the presence of stressed neurons,
PSAP was greatly upregulated and easily detected in the media by
immunoblotting. Therefore, to fully reveal the agonist activity of TX14
(A), it is important to ensure that the receptors are not persistently
exposed to endogenous or media-derived PSAP.
Taken together, our results demonstrate that prosaptide TX14
(A) (and, by extension, PSAP) are the natural ligands of GPR37L1/
GPR37 and confirm that in their native environment, the astrocyte,
these receptors couple to the Gi cascade as originally reported (Meyer
et al., 2013). Their native signaling is, however, lacking or suppressed in
FIGURE 7 Working model of the neuroprotective role of astrocytic
GPR37L1/GPR37 based on the evidence presented in this study.
Damaged neurons release diffusible “SOS” factor(s) which trigger
release of PSAP. PSAP acts on GPR37L1 on astrocytes and activates
release of diffusible neuroprotective factor(s) [Color figure can be
viewed at wileyonlinelibrary.com]
FIGURE 6 Co-cultured astrocytes protect cortical neurons against
oxidative toxicity partially through GPR37L1/GPR37 signaling in
astrocytes. (a) Experimental design: (A—stressed neurons (blue) in
absence or presence of astrocytes (green) on a culture insert; B—
depletion of PSAP from the media with anti-PSAP antibodies; C—
GPR37L1 and GPR37 knock-down in astrocytes co-cultured with
neurons; D—GPR37L1 and GPR37 knock-down in neurons in the co-
culture system. Neurons were treated with H2O2 (250 μM) for 1 hr, or
staurosporine (100 nM) or rotenone (50 μM) for 2 hr. Stressors were
then removed and inserts with astrocytes were introduced. LDH
assay was carried out 24 hr later. (b) Astrocytes protect cortical
neurons against H2O2-induced stress, the effect saturates at ~75 k
astrocytes per co-culture (n = 5, triplicates, ***p < .001 vs. control
[no astrocytes insert], ****p < .0001 vs. groups with less than 50 k
astrocytes, one-way ANOVA with Tukey's post hoc analysis). (c) TX14
(A) has a weak protective effect on neurons against oxidative stress
(n = 6, triplicates, ***p < .001, ****p < .0001 vs. 50 nM TX14
(A) group (effect of 50 nM is not significant, one-way ANOVA with
Bonferoni's post hoc analysis). D: PSAP depletion or GPR37L1/
GPR37 knock-down selectively in astrocytes significantly attenuates
the protective effect of astrocytes on neurons pre-exposed to
oxidative stressors (n = 6, triplicates, ***p < .001 vs. indicated group,
one-way ANOVA with Turkey's post hoc analysis) [Color figure can be
viewed at wileyonlinelibrary.com]
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cell lines (such as transiently transfected HEK293 cells) used in β-arrest-
ing-based screening assays, indicating that for correct coupling GPR37L1
and GPR37 may require as yet unknown intracellular partners present in
astrocytes. This would not be a unique situation since some other recep-
tors, such as CGRP receptor, are known to require co-expression of
receptor-associated proteins. Of note, astrocytes express very high
levels of syntenin-1, which is important for trafficking of GPR37
(Dunham, Meyer, Garcia, & Hall, 2009). It is conceivable that its role
includes more than just trafficking. Given the powerful glio-protection
and neuroprotection mediated by these receptors and since GPCRs are
the most “druggable” class of proteins currently known, GPR37L1 (and
GPR37, if they can be separated pharmacologically) become highly valu-
able targets for development of novel neuroprotective therapies.
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